KCNJ8 and cardiac hypertrophy: Natakalim, a novel KATP channel opener, can reverse vascular endothelial cell dysfunction caused by homocysteine and hypoxia and prevent the progression of cardiac hypertrophy to failure induced by pressure overload by selectively opening the SUR2B/Kir6.1 channel subtype (12–14).